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Abstract
Femoral head necrosis (FHN) is a disease process resulting from inadequate blood perfu-
sion of subchondral bone. While the etiology of this disease is still not fully understood, 
there are multiple traumatic and atraumatic factors that are associated with the disease. 
Pathophysiology of the disease is characterized by the death of bone marrow and osteo-
cytes. If left untreated, the disease may progress to joint collapse. While initial stages of 
the disease are asymptomatic, painful limitation of active and passive motion of the hip 
is eventually present. The current body of literature cannot identify an optimal treat-
ment protocol for FHN. Postcollapse cases require surgical intervention, core decom-
pression, or total hip arthroplasty. However, current strides in conservative management 
are being made. One of the possible conservative modalities that may effectively delay 
hip arthroplasty or even prevent the need for a surgical approach is hyperbaric oxygen 
(HBO
2
) therapy. HBO
2
 increases extracellular oxygen concentration and reduces cellular 
ischemia and edema by inducing vasoconstriction. Studies have reported radiographic 
improvement, reduction in pain, and increases in range of motion for early stages of the 
disease. Hyperbaric oxygen therapy has also been shown to stimulate angiogenesis and 
enhance osteoclast and osteoblast function for remodeling and repair.
Keywords: hyperbaric oxygen, femoral head necrosis, mechanisms of action, 
inflammation, cytokines
1. Introduction
Femoral head necrosis (FHN), also named avascular necrosis or osteonecrosis of the femoral 
head, is a common multifactorial disorder that affects patients of any age and can result in 
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substantial clinical morbidity [1]. Osteonecrosis is characterized by the lack of or inadequate 
blood flow to the bony tissue that leads to death of the osteocytes and the bone marrow [2].
As reported by Parsons and colleagues, it is most common in the second to fifth decades 
of life, and the typical patient is a male, in his mid-30s [3]. Epidemiology reveals between 
10,000 and 20,000 new cases of FHN diagnosed each year in the United States [4]. In the 
western countries, the prevalence of the disease is at a mean age of 39 years, and the 10% of 
hip replacements performed is due to FHN [5]. Femoral head collapse, hip joint degenerative 
lesions, and subsequent long-term disability represent possible adverse consequences of the 
untreated or nondiagnosed FHN [6]. In particular, it is estimated that more than 70% of femo-
ral heads with osteonecrosis will proceed to collapse, requiring prosthetic joint replacement 
within 3–4 years of diagnosis [7]. About that, it is responsible for 5–18% of all hip replace-
ments performed [4]. Moreover, similar pathophysiology can occur in other articular districts 
(i.e., the femoral condyle, the wrist, the head of the humerus, and the distal talus) caused by 
comparable avascular syndromes. Multifocal osteonecrosis is defined as a disease involving 
three or more separate anatomic sites concurrently or consecutively [8].
Radiographic diagnosis is now possible at a former stage; thus, orthopedic physicians can 
identify the disorder earlier [9].
Hyperbaric oxygen (HBO) therapy is one of the proposed treatments. Indeed, tissue oxygen-
ation promotes angiogenesis inducing edema reduction [1]. Moreover, by reducing intraos-
seous pressure, venous drainage is restored and the microcirculation is improved [10]. With 
restriction to the stage considered, Camporesi et al. showed that HBO should be considered 
the primary treatment modality in any patients and especially in young patients where 
the goal is to delay total hip arthroplasty as long as possible [5]. Therefore, the European 
Community accepted femoral head necrosis as an indication for hyperbaric oxygen therapy 
(HBOT) during the Consensus Conference in Lille, France [11].
Originally, the relation between femoral head necrosis and HBOT was deeply analyzed on a 
specific chapter published on Hyperbaric Medicine Practice [12]. It reported precise charts of 
patient results and a detailed review of the literature until 1997, as well as the different pathologi-
cal outcomes and rationale for treatment [13]. Recently, an extended report on this topic has been 
proposed by Bosco and colleagues [1, 14]. They precisely updated the scientific literature until 
2016 and summarized, for the paper’s eligibility for the study, the number of patients, aim, inclu-
sion/exclusion criteria, and obtained outcomes. Even though management, care, and therapeutic 
options are clearly stated for the pathology, available results differ from each other according to 
the stratification criteria and the particular stage of the disorder [15]. The present chapter aims 
to review more recent evidence from the scientific literature, outlining the physiology and the 
present status of pathology and therapy for femoral head necrosis. In particular, we focused on 
therapeutic mechanisms of action for hyperbaric oxygen (HBO
2
) on femoral head necrosis.
2. Etiology
In studying FHN, the absence of a bipedal mammalian model limits our knowledge among 
risk factors and pathogenesis of the disease. Additionally, completing longitudinal studies is 
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difficult for researchers and clinicians. However, scientific community agrees that ischemia 
plays a main role in the pathogenesis. As aforementioned, FHN is a multifactorial disease in 
which both genetic and daily-living factors lead to the pathology. When evaluating patients 
with osteonecrosis, physicians should first differentiate between primary (“idiopathic”) osteo-
necrosis and secondary osteonecrosis [16]. Although the etiology of secondary osteonecrosis has 
not been clearly delineated, risk factors include both traumatic and nontraumatic conditions 
(i.e., corticosteroid use, alcohol consumption, smoking, coagulation abnormalities, etc.) [17].
Traumatic events may lead to bone fracture or at worst to femoral head displacement; since 
the trauma occurs, it directly results in disruption of the femoral head blood supply [18]. 
Malizos et al. distinguished different pathogeneses in patients with subcapital fracture and 
patients with hip dislocation. In the first case, the 10–20% of the vascularization of femoral 
head is preserved from ligamentum teres. Conversely, as the hip dislocation occurs, blood 
supply is interrupted, and perfusion depends on the integrity of retinacular vessels [2].
Otherwise, nontraumatic osteonecrosis is frequently associated with pathologies where 
corticosteroid treatment is required (i.e., systemic lupus erythematosus, organ transplant, 
lymphoma, etc.). A report described the case of a female patient who was just under 
18 years old when she underwent surgery due to bilateral osteonecrosis of the femoral 
condyles that developed in the course of treatment of a hematological malignancy [19]. 
Even though, scientific literature does not know the exact dose of steroids necessary 
to induce osteonecrosis, the higher the dose the greater the risk. Indeed, daily mean or 
peak dose taken seems to be more implicated than cumulative or duration of therapy 
[3]. Furthermore, an addiction to alcohol and long drinking period were reported as risk 
factors for FHN. In comparing gender difference, studies indicated for males a greater 
frequency of alcohol-induced FHN with respect to females [20, 21]. Indeed, Shimizu et al. 
showed a bigger susceptibility of males in developing FHN in response to alcohol con-
sumption. Specifically, females did not develop osteonecrosis for alcohol consumption for 
both short-time and long-time periods. However, further investigations are needed among 
sex-related factors responsible for this evidence [20].
Further risk factors of FHN can be identified in bone marrow transplantation, as well as meta-
static malignancies, and pregnancy. Additionally, it may be associated with pathologies as 
hyperuricemia, pancreatitis, and leukemia or lymphoma [9, 14].
3. Pathophysiology
FHN physiopathology is characterized from a complex series of events that couple a usual 
pathway of cellular death and osteogenic processes [14]. Pathogenic course begins with two 
associated mechanisms: edema of interstitial marrow and necrosis of hematopoietic cells and 
adipocytes. Histological signs appear nearly 24–72 h following anoxia, even though osteocyte 
necrosis is evident after approximately 2–3 h of oxygen deprivation [22, 23]. These stimuli 
induce bone remodeling processes. Originally, inflammatory signs (i.e., reactive hyperemia 
and capillary revascularization) surround the necrotic area. Thus, this mechanism initiates 
bone repairing in which new bone hardly tries to remove and substitute dead tissues [9].
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However, bone remodeling proceeds inefficiently because of dead trabeculae, where new liv-
ing bone is placed. Moreover, osteolysis exceeds osteogenesis, and this results in loss of struc-
tural integrity of trabeculae, with subsequent subchondral fracture and joint incongruity [24].
Altered subchondral vascularity is the basic pathophysiological hallmark for FHN [9]. Kiaer 
and colleagues indicated that a blood supply drop of 60% will result in an intraosseous pO
2
 
decrease, from 75 mmHg to 50 mmHg [25]. Consequently, it will cause evident ischemia.
Different pathogenic mechanisms can result in FHN. Cytotoxicity due to exposure to radia-
tion, chemotherapy, or thermal injury causes direct death of marrow cells and osteocytes, 
though this was not shown in vivo yet [18]. Additionally, three main pathogenic mechanisms 
can lead to ischemic conditions and subsequent femoral head necrosis:
1. Vascular interruption by fractures or dislocation (i.e., traumatic osteonecrosis). Femoral 
neck fractures or hip displacement usually result in extra-osseous arterial involvement. 
Specifically, when fracture occurs inside the joint capsule, vessels that oxygenate the sub-
chondral bone suffer a direct trauma. A relatively high incidence of FHN in patients with 
these fractures has been reported.
2. Intravascular coagulation and microcirculatory thrombosis. Different pathways can lead 
to the same vascular obstructions that mean sickle cell aggregations, clots, or lipid thrombi 
[6]. Thrombotic emboli can occur both in arteriosus and venous areas in samples of oste-
onecrotic tissue; in some animal models, they have been associated with osteocyte necrosis 
[3]. The prevalence of sickle cell anemia-induced osteonecrosis stands between 37 and 50%. 
The weak arterial network in the hip joint eases vascular occlusion by sickled cells [16]. In 
these patients, low oxygen tension environments are hypothesized to trigger hemoglobin 
precipitation which leads to erythrocyte sickling [6]. Moreover, the complication rate for 
patients with sickle cell disease undergoing orthopedic procedures is significantly higher 
than that for patients without sickle disease. Consequently, early and alternative interven-
tions are critical to successfully delay total hip arthroplasty.
Also, coagulation disorders are implicated in FHN. For example, genetic defects result-
ing in hypofibrinolysis or thrombophilia may lead to increased thrombi formation and 
blood flow obstruction in the bony tissues. Nevertheless, using a case-control methodol-
ogy, elevated coagulation factor levels have been reported in patients with osteonecrosis 
showing the absence of known genetic defects [14]. Jarman et al. showed that coagulation 
abnormality-derived osteonecrosis is worsened by testosterone therapy, and its develop-
ment may be slowed or stopped by discontinuation of therapy and, thereafter, antico-
agulation [26]. Indeed, Guo and colleagues suggested the use of anticoagulant therapy for 
primary FHN. However, anticoagulants cannot play a protective role on secondary FHN 
[27]. Coagulation pathologies recognized before femoral head necrosis simplify therapeu-
tic approach, preserving joints.
3. Intraosseous extravascular compression from lipocyte hypertrophy or Gaucher cells. It 
can also result from hemorrhage, infection, high bone marrow pressure, marrow infiltra-
tion, and bone marrow edema [18]. Physiologically, since the pressure increases within 
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the intraosseous extravascular region, microcirculation in vessels crossing the tissue de-
creases. Nevertheless, it is not a regular event. Many times, steroid consumption influ-
ences lipid metabolism leading to fat production in bone stem cells and drug-induced 
osteoporosis and osteonecrosis [3, 28]. This process will soon result in fat cell hypertro-
phy. Subsequently, intraosseous pressure will rise and ischemic condition will occur [29]. 
Though osteonecrosis is mostly associated with hypercholesterolemia and/or hypertri-
glyceridemia, the osteonecrosis-related lipid abnormalities have been well documented 
with the Gaucher disease (GD) [16]. Gaucher disease (GD) is a lysosomal storage disorder, 
caused by an impaired function of β-glucocerebrosidase, which results in accumulation of 
glucocerebroside in cells, and altered membrane ordering [30]. However, microcirculatory 
blood flow blockage is not necessarily the starting pathological event. Lysosomal contents 
released from Gaucher cells may damage vessel membrane, with localized osteonecrosis 
that may extend to bordering areas [31]. Skeletal involvement is typical in mature patients 
suffering from type 1 Gaucher disease, with a radiological evidence described in 93% of 
cases. Among these, the 30% presents osteonecrosis [31].
4. The fourth physiopathological mechanism is under investigation: extra-osseous venous 
obstruction. Although impairment of the extra-osseous veins happens, there is still an un-
certainty whether it is a cause or effect. Additionally, it possibly has limited clinical mean-
ing [6]. Recently, Shah et al. reviewed literature on this topic, and they investigated in-
creased intraosseous pressure as a pathogenic process in FHN. In particular, bloodstream 
interruption or stasis in the venous side has been associated with increased pressure in 
osteonecrotic samples [6].
Since the seventies, scholars studied dysbaric osteonecrosis and explained radiographic fea-
tures of this pathology [32]. It is an avascular bone necrosis induced by exposure to hyperbaric 
environments, typical for diverse and compressed air workers [33]. A literature review on 
dysbaric osteonecrosis evidenced that incomplete decompression procedures lead to blood 
supply decrease and subsequent osteonecrosis; this is due to the entry of nitrogen bubbles in 
the fatty marrow-containing shafts of long bones [34]. Studies clearly stated the approach to 
be used, outlining diving decompression schedules [33].
4. Rationale for using hyperbaric oxygen
HBO
2
 therapeutic mechanisms of action are based on elevation both of the partial pressure of 
inspired O
2
 and of the hydrostatic pressure. The latter mechanism contributes to determine 
the compression of all gas-filled spaces in the body (Boyle’s law), and it is fundamental to 
allow an effective treatment of those conditions where gas bubbles are present in the body 
and cause the disease (e.g., intravascular embolism or decompression illness with intravascu-
lar or intra-tissue bubbles) [35, 36]. However, most patients treated with HBO
2
 do not suffer 
from bubble-induced lesions, deriving their clinical improvements from the other mechanism 
of HBO
2
 therapy: the elevated O
2
 partial pressures achieved. High O
2
 partial pressures so 
obtainable in various tissues lead to the increase in the production of reactive O
2
 species (ROS) 
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as well as of reactive nitrogen species (RNS), these last ones due to hyperoxia [37]. Controlled 
studies have already shown as the clinical efficacy from HBO
2
 depends on modulation of 
intracellular transduction cascades, driving to synthesis of growth factors, promoting the 
wound healing, and ameliorating postischemic and post-inflammatory injuries [36].
The actual inability to establish which will be the correct dose of HBO
2
 to administer in each 
case is still depending on the lack in Level 1 evidence [1, 11]; as a matter of fact, the current 
scientific literature does not yet allow a clear identification of the optimal treatment protocol.
Nevertheless, HBO
2
 is positioned among the possible and feasible therapies which allow to 
provide a delay in undergoing hip arthroplasty surgery; it is a reasonable postulate that such 
therapy can show a beneficial effect without having the invasiveness of a surgical approach.
HBO
2
 increases extracellular oxygen concentration and reduces cellular ischemia and edema 
by inducing vasoconstriction [38]. Studies have already reported radiographic improvement 
in FHN at stage I according to the Steinberg classification, as well as a better pain control, com-
pliance, and range of motion (ROM) in FHN at Ficat stages I–II [36]. Amid the possible effects 
of HBO
2
, there is a reduced bone marrow pressure, leading to a significant pain relief, and 
an increased oxygen delivery to ischemic cells, thus relieving compartment syndrome so to 
prevent a progression in a further necrosis, stimulating angiogenesis and oxygen-dependent 
cells, and enhancing osteoclast and osteoblast function for remodeling and repair. Moreover, 
HBO
2
 is also able to stimulate the multipotent fibroblasts in the bone marrow with an addi-
tional aid in the osteogenesis process [37].
In FHN treatment HBO facilitates oxygenation of hypoxic tissue and reduces edema by creat-
ing a high concentration of dissolved oxygen and inducing vasoconstriction. This may explain 
the early pain relief noticed in patients treated with this modality; by saturating the extra-
cellular fluid with diffused oxygen, HBO treatment will lead to a better oxygenation of the 
ischemic bone cells, independently of circulating hemoglobin and without the extra-energy 
requirement to provide for the dissociation of oxygen from hemoglobin. Late effects of HBO 
are bone resorption, revascularization, and osteogenesis [5, 36].
Yang et al. quantitatively evaluated the hemodynamic flow in animal models with steroid-
induced FHN by using multi-slice CT perfusion imaging. Especially in the early stage, they 
assessed how HBO therapy resulted in regional blood flow improvement in the ischemic tissues. 
Additionally, they found high-grade new bone formation and a well-regenerated hematopoietic 
tissue [39]. Moreover, recent studies focusing among osteoblasts differentiation and suppres-
sion osteoclasts showed positive results due to hyperbaric oxygen treatment. In particular, HBO 
shifted the balance between bone formation and bone resorption promoting regeneration [40, 41].
5. Clinical presentation
An early detection of FHN is of paramount importance as clinical success of the therapy is 
closely related to the stage which the treatment started in [42]. There are several procedures 
capable to intercept a suspected FHN at the onset or eventual early stages of the disease: 
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at the present time, histological studies, scintigraphy, functional bone evaluation, radiogra-
phy, magnetic resonance imaging (MRI), and computer-assisted tomography (CAT) are the 
most current diagnostic methods available. At an early stage, FHN is usually asymptomatic or 
characterized by slight pain radiating to the knee and/or ipsilateral buttock.
It may present with a limited range of hip movement as well as stabbing pain, especially dur-
ing a forced intra-rotation. FHN should be considered if the patient feels pain in the hips and 
has no risk factors in his clinical history. In particular, plain radiographs can often appear as 
normal in the early stages of necrosis. Patients with a history of previous necrosis should be 
observed for bilateral FHN; this condition has been reported up to 70% of the observations [43].
Classification systems currently in use for FHN include the Ficat and Steinberg systems [15].
The Ficat classification substantially relies on standard radiographic presentations, where 
phase I shows normal images; phase II indicates a normal contour, with evidence of a bone 
remodeling; stage III is characterized by subchondral collapse or flattening of the femoral 
head; and phase IV indicates a narrowing of the joint space, with secondary degenerative 
changes in the acetabulum. The Ficat classification system is however based on radiographic 
imaging; therefore, the real size of the lesion cannot be quantified up to a more proper and 
accurate measure of the radiological appearance of the disease.
Steinberg expands the Ficat system into six stages, including quantification of involvement 
of the femoral head within stages I–VI, with three further subsets each: mild (less than 15% 
radiographic involvement of the head’s articular surface), moderate (with a 15–30% involve-
ment of the head’s articular surface), and severe (greater than 30% involvement of the head’s 
articular surface) stages.
Recently, the Association Research Circulation Osseous (ARCO) has recommended a third 
standardized classification system relying on an interpolated comparison of different proce-
dure findings: radiographic, MRI, bone scan, and histologic findings [15]. Anyhow, not even 
this can eliminate completely the intrinsic operator-dependent variability, making Ficat and 
ARCO classification systems still not sufficiently reliable to assess FHN occurrence [44].
FHN is currently diagnosed by plain anterior-posterior and frog leg lateral radiographs of the 
hip, followed by MRI; this is considered the most accurate benchmark. Other existing tools for 
assessing the FHN presentation, such as venography, bone marrow pressure measurements, 
and core biopsy, are rarely used.
6. Clinical management of femoral head necrosis
Many therapeutic modalities have been proposed, and their effects were recently reviewed by 
Sen [45] and Zalavras and Lieberman [17].
Where untreated, FHN is a progressive disease process in affected hip showing an intact 
articular survival rates of less than 60% in 5 years; furthermore, the survival rate in stage III 
is less than 10% [10, 13].
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Actual clinical evidence clearly demonstrates that HBO is able to lead to an extended duration 
of the survival rate of the affected hips:
• Reis et al. treated 12 patients with stage I ANFH, one daily HBO session, for a total of 100 
HBO treatments. They reported that 81% of HBO-exposed patients returned to normal MRI 
vs. only 17% in the untreated group [46].
• A double-blind, randomized, controlled, prospective study evaluated hyperbaric oxygen 
therapy on a cohort of 20 patients with unilateral FHN (Ficat stage II) [5]. All patients were 
treated with either compressed oxygen or compressed air (HBA); each patient received 30 
treatments of HBO or HBA for 6 weeks. After the initial 6-week treatment, the blind was bro-
ken: all HBA patients were then offered to undergo HBO treatment. From this point on, the 
study veers toward an observational design study. Range of motion (ROM), stabilometry, 
and pain were assessed at the beginning of the study and after 10, 20, and 30 treatments by 
a blinded physician. Resonance images were obtained at a pretreatment stage, at 12-month 
post-HBO, and at a final 7-year follow-up (Figure 1). There was a significant pain improve-
ment after HBO, with significance after 20 treatments on average. ROM improved likewise 
during HBO, for all parameters, after 20–30 treatments. At 7-year follow-up, all patients re-
mained substantially pain-free and none required hip arthroplasty; an almost complete ra-
diographic healing of the osteonecrosis was observed in seven of nine hips. Hyperbaric oxy-
gen therapy does appear to be a viable treatment modality in patients with Ficat II FHN [5].
• Koren et al. used HBO to treat 68 patients (78 joints) with stage I and II disease; these au-
thors’ HBO protocol involved breathing 100% oxygen at 2.0–2.4 ATA for 90 min, for a total 
of 20 treatments. They reported that 88% of the HBO treatment group had improvement 
on MRI and a 93% survival rate of the joints at 11.1 ± 5.1 year of follow-up of 54 patients 
(58 joints) [10].
• Recently, the long-term effect of HBO in 217 patients with stage I, II, and III ANFH has 
been investigated [47]. These results validated previous findings: HBO shows itself to be 
able to significantly improve hip condition, alleviate pain, and, more importantly, avoid 
hip surgery in most of patients presenting a stage II disease. Moreover, this study further 
shows the beneficial effects of HBO in stage III patients, where hip pain is significantly 
reduced in most patients, hip surgery is avoided in approximately half of the patients, and 
the obtained results are maintained for up to 4 years [47].
One of the first studies, proposed by Baixe and colleagues, affirmed that 20 HBO treatments 
were sufficient for pain reduction [48]. As previously reported, Camporesi and colleagues 
showed that after 20–30 treatments patients were substantially pain-free [5]. However, 20 
HBO treatments are not sufficient for the complete hip healing.
Even though there are many evidences among beneficial effects of HBO, there is still no agree-
ment on the number of HBO treatments required. The recent work by Bosco and colleagues 
generated a mean number of 83.3 ± 24.8 [47], while in the study by Koren et al., the average 
number of treatments was 78.3 ± 24.2: this in itself is remarkably close [10]. In other papers the 
number of treatments widely ranges from 20 to 120 [49].
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Figure 1. MRI pictures of a patient treated with HBO. (A) A pretreatment MRI exhibiting bone defect. (B) A twelve-
month MRI showing near complete resolution of bone defect. (C) A seven-year follow-up MRI showing no change in 
bone defect [5].
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A large number of sessions showed to be effective on pain relief and mobility improvement 
and avoided arthroplasty, in about 80% of cases. In particular, about 90% of Ficat I and II 
patients and half of Ficat III patients after HBOTs had no more need of surgery and all related 
complications for at least 4 years [47].
7. New perspectives
Despite the several clinical studies that support the benefits of HBOT in patients afflicted with 
osteonecrosis [1, 5], therapy is still not worldwide approved. This could be due to several fac-
tors including the apparent high number of HBO treatments necessary plus limited amount of 
clinical evidence for FHN, the majority of the evidence relies on ex vivo and in vitro studies, 
and the molecular mechanisms responsible for the regenerative responses of HBOT are still 
debatable. Thus, the underlying mechanism of action is still unclear.
A recent study investigated HBO upregulation on serum osteoprotegerin (OPG) and/or inhibi-
tion of osteoclast activation [50]. Twenty-three patients suffering from unilateral FHN at stage 
I, II, and III consented to the study: patients received standard HBOT; nineteen patients com-
pleted the study. Serum OPG levels were obtained at the beginning of HBOT (T
0
), after 15 
sessions (T
1
), after 30 sessions (T
2
), after a 30-day break (T
3
), and at the end of our treatment pro-
tocol, after 60 sessions (T
4
). Magnetic resonance imaging (MRI) was obtained at T
0
 and about 
1 year from the end of HBO treatments to compare pre-HBOT with post-HBOT lesion size.
The findings were:
• HBOT reduced pain symptoms in all patients.
• HBOT significantly reduced lesion size in all stage I and II patients and in 2 of 11 stage III 
patients.
• HBOT increased serum OPG levels, but receptor activator of nuclear factor kappa-B ligand 
(RANKL) levels did not change.
These evidences proposed an influence of HBO on the immune system and inflammatory 
processes. Indeed, one of the initial studies by Lukich et al. suggested an immunosuppressive 
effect of HBO therapy in patients suffering from rheumatoid arthritis [51]. Later, other studies 
reinforced these findings. Specifically, authors showed TNF-alpha and interleukin-1β (IL-1β) 
inhibition after HBO therapy in indomethacin-induced enteropathy and in chronic constric-
tion injury-induced neuropathy [52, 53]. The following are some examples of tissue cytokine 
changes proposed after HBO.
IL-1β is a pro-inflammatory cytokine that responds to injury or infection by binding to the 
type-1 IL-1 receptor (IL-1R) and IL-1R accessory protein [54]. Although belonging to a struc-
turally different cytokine class, IL-1 resembles many of the biological activities of TNF-α; 
IL-1 activation results in downstream activation of NF-kB and JNK [55, 56]. Fukushima et al. 
found that IL-1β has a stimulatory effect on osteoclast formation via increasing expression of 
RANKL [57]. IL-1β, like TNF-α and IL-6, is produced by stromal cells and monocytes. These 
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cytokines can synergistically stimulate osteoclast differentiation leading to a net increase in 
RANKL activity and control their own expression [56].
IL-6 has been demonstrated to exhibit a dual effect on osteoclastic differentiation. During the 
inflammatory process, monocytes/macrophages produce IL-6, which can directly stimulate 
pre-osteoclast cells to be differentiated and activated [56]. In addition, IL-6 can stimulate stro-
mal/osteoblastic cells to produce certain effectors, namely, IL-6, which will then promote osteo-
clastic differentiation [56]. Thus, there is a dual contribution, direct and indirect interaction, in 
which IL-6 can upregulate bone turnover. In vivo studies of IL-6 found that in transgenic mice 
with overexpressed IL-6 there is a greater bone turnover, reduced osteoblasts, and increased 
osteoclasts leading to osteopenia [58]. Correspondingly, IL-6-deficient mice displayed reduced 
osteoclasts and lower levels of bone erosion [59]. Kurokouchi and colleagues found TNF-α to 
increase the expression of IL-6 and ICAM-1 genes [60]. Hence, lower levels of TNF-α resulting 
from HBOT exposure could explain the reduction in IL-6. This effect, in summation with the 
synergistic effects of TNF-α, IL-6, and RANKL, could ultimately lead to decreased levels of 
osteoclastogenesis and, hence, greater resolution for the patient [56]. In the case of FHN, HBOT 
results in a decreased amount of circulating TNF-α. We propose the following mechanism: 
HBOT leads to reduced levels of TNF-α leading to decreased binding of TNF-α to the p55r type 
1 receptor and thus decreased levels of NF-kB activation [56]. This reduction in RANKL would 
tip the balance of OPG/RANKL in the direction of osteoblast activation [50].
Understanding the HBOT’s molecular mechanism of action remains the best approach in order 
to gain greater recognition for this treatment and to achieve earlier resolution for patients.
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